Antibody Specificity and Validation: How to Confirm Your Antibody Works

An antibody is only as useful as its specificity. An antibody that binds the wrong target, or binds the right target plus several unintended ones, can generate misleading data that wastes months of work. The antibody reproducibility crisis in biomedical research is estimated to cost billions of dollars annually — and poor antibody specificity is a leading contributor.

This guide covers what antibody specificity really means, why cross-reactivity happens, and how to validate that your antibody performs as expected in your specific experimental system.

1. What Is Antibody Specificity?

Antibody specificity refers to the ability of an antibody to bind exclusively to its intended target (the cognate antigen) and not to unrelated proteins. In practice, specificity is not absolute — it is always relative to a defined experimental context. An antibody may be highly specific in one application (e.g., WB under denaturing conditions) but cross-reactive in another (e.g., IHC on a different tissue type where homologous proteins are expressed).

This is why validation must be performed in the context of your specific application, tissue, and species — not assumed from the datasheet alone.

2. Why Cross-Reactivity Happens

3. The Five Pillars of Antibody Validation

The International Working Group for Antibody Validation (IWGAV) proposed five conceptual pillars for validating antibody specificity. Not every experiment requires all five, but using at least two independent strategies provides strong evidence of specificity.

4. Understanding Species Reactivity

Antibody datasheets list "species reactivity" — the species in which the antibody has been tested and confirmed to bind the target. This typically includes "tested" species (experimentally validated) and sometimes "predicted" species (based on epitope sequence homology).

Tested reactivity means the antibody has been experimentally validated in that species using at least one application (e.g., WB on human cell lysate). This is the most reliable indicator.

Predicted reactivity is based on sequence alignment: if the epitope sequence is 100% conserved between human and mouse, the antibody is predicted to cross-react with mouse. However, predicted reactivity is not guaranteed — protein folding, post-translational modifications, and accessibility can affect binding even with 100% sequence identity.

Not listed does not necessarily mean the antibody will not work in that species. It may simply mean testing has not been performed. If sequence homology in the epitope region is high (> 85%), empirical testing is often worthwhile.

5. Validation Checklist for Your Lab

Before using a new antibody in a critical experiment, run through this checklist:

1. Check the datasheet: Is your application listed as validated? Is your species listed as tested (not just predicted)?

2. Run a positive control: Use a cell line or tissue known to express the target at detectable levels. If no signal, troubleshoot protocol before blaming the antibody.

3. Run a negative control: Use a cell line or tissue known to lack the target (KO line, or a cell type that does not express the gene). If signal is present in the negative control, specificity is questionable.

4. Check molecular weight (WB): Does the band appear at the expected molecular weight? Additional bands may indicate cross-reactivity, degradation products, or post-translational modifications. Refer to UniProt for predicted MW. For detailed WB troubleshooting, see our Common Western Blot Issues guide.

5. Titrate the antibody: Use a dilution series to find the optimal concentration that maximizes signal-to-noise. Over-concentration is the most common cause of non-specific background. See our Antibody Dilution Optimization guide for step-by-step titration strategies.

6. Compare with an independent antibody or method: If possible, confirm the result with a second antibody (different clone or different epitope) or an orthogonal technique (qPCR, mass spectrometry).

For IHC-specific validation, including marker selection by tumor type and multi-antibody panel design, see our IHC Panel Design for Cancer Diagnosis guide. If you encounter high background or non-specific staining in IHC, our IHC Troubleshooting guide covers common causes and fixes.

6. Frequently Asked Questions

Q: Does "validated for WB" mean the antibody will also work for IHC?

Not necessarily. WB detects denatured proteins (linearized epitopes), while IHC detects proteins in their native or partially recovered conformation in fixed tissue. An antibody that works well on WB may fail on IHC if its epitope is not accessible after fixation and antigen retrieval, or vice versa. Always use antibodies validated for the specific application you intend to perform. For step-by-step IHC protocols, see our IHC Staining Protocol guide.

Q: I see extra bands on my Western blot. Does this mean the antibody is non-specific?

Not always. Extra bands can result from: (1) protein isoforms or splice variants of the target protein; (2) post-translational modifications (glycosylation, ubiquitination) that shift the apparent MW; (3) proteolytic degradation products; or (4) genuine cross-reactivity. Compare the observed bands to predicted isoform sizes in UniProt. If the extra bands disappear in a KO cell lysate, they are likely target-related. If they persist, they are cross-reactive. For more WB band interpretation tips, see our Western Blot Troubleshooting guide.

Q: Can I trust "predicted" species reactivity?

Use it as a starting point, not a guarantee. If the immunogen sequence is 100% identical between human and mouse, there is a high probability the antibody will cross-react with mouse protein. However, you should always confirm experimentally with a positive control from the predicted species. Differences in protein expression level, folding, glycosylation, or fixation-induced epitope masking can all affect binding regardless of sequence identity.

Q: How do I find a KO-validated antibody?

Many suppliers now offer KO-validated antibodies with supporting data showing loss of signal in CRISPR/Cas9-generated knockout cell lines. Check the product page or datasheet for "KO validated" or "knockout verified" status. You can also search public databases like CiteAb or Antibodypedia for antibodies with published validation data. If KO validation is not available, consider generating your own KO control using CRISPR in a cell line you are already using.

Q: Is a monoclonal antibody always more specific than a polyclonal?

A common misconception. A monoclonal antibody is specific for a single epitope, but that epitope may be shared across related proteins. A polyclonal antibody recognizes multiple epitopes, increasing overall signal but also increasing the probability of off-target binding. Neither type is inherently more specific than the other — specificity must be validated experimentally for each antibody in each application. For a detailed comparison, see our Monoclonal vs. Polyclonal Antibodies guide.

References

1. Uhlen M, Bandrowski A, Carr S, et al. A proposal for validation of antibodies. Nat Methods. 2016;13(10):823-827. doi: 10.1038/nmeth.3995

2. Bradbury A, Plückthun A. Reproducibility: standardize antibodies used in research. Nature. 2015;518(7537):27-29. doi: 10.1038/518027a

3. Baker M. Reproducibility crisis: blame it on the antibodies. Nature. 2015;521(7552):274-276. doi: 10.1038/521274a

This article is provided for educational purposes only. For technical support, contact order@abinscience.com.